What question did this study set out to answer?

The aim is to evaluate the prognostic value of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in predicting disease progression in ALD-related myelopathy.

April 10, 2026Open Access

Prognostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in ALD‐Related Myelopathy

Key Points

The aim is to evaluate the prognostic value of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in predicting disease progression in ALD-related myelopathy.
Analyzed baseline plasma levels of NfL and GFAP
Assess disease progression in adult X-ALD patients
Utilized statistical comparisons for biomarker performance
Baseline plasma NfL accurately predicts spinal cord disease progression
GFAP shows limited standalone effectiveness as a biomarker
Support for using NfL in patient stratification for clinical trials

Abstract

Baseline plasma NfL is a robust prognostic biomarker for spinal cord disease progression in adult X-ALD and supports its use for patient stratification in clinical trials, whereas GFAP shows limited standalone utility.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Eda Kabak

Marije M C Voermans

Hans Heijst

Journals

Annals of Clinical and Translational Neurology

Actions

Institutions

University of Amsterdam

Amsterdam University Medical Centers

Amsterdam Neuroscience

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Prognostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in ALD‐Related Myelopathy

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study